Research programme - malaria vaccines - Aduro/Protein Potential
Latest Information Update: 03 Nov 2015
At a glance
- Originator Aduro BioTech
- Developer Aduro BioTech; Protein Potential
- Class Vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Malaria